Xinmin Yu

527 total citations
24 papers, 382 citations indexed

About

Xinmin Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Xinmin Yu has authored 24 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 5 papers in Surgery. Recurrent topics in Xinmin Yu's work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (5 papers) and Cancer Genomics and Diagnostics (5 papers). Xinmin Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (5 papers) and Cancer Genomics and Diagnostics (5 papers). Xinmin Yu collaborates with scholars based in China, United States and Japan. Xinmin Yu's co-authors include Yaping Xu, Qinghua Deng, Shenglin Ma, Weimin Mao, Qixun Chen, Yiping Zhang, Zhengbo Song, Yan Sun, Qixun Chen and Xiaojiang Sun and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and BMC Cancer.

In The Last Decade

Xinmin Yu

23 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xinmin Yu China	11	252	239	101	93	46	24	382
Gustavo Schvartsman Brazil	11	201 0.8×	370 1.5×	118 1.2×	101 1.1×	42 0.9×	31	488
Chaitali Nangia United States	9	158 0.6×	197 0.8×	55 0.5×	77 0.8×	43 0.9×	34	330
Maria Alessandra Calegari Italy	10	109 0.4×	220 0.9×	56 0.6×	89 1.0×	70 1.5×	43	361
S.T. Kim South Korea	9	210 0.8×	281 1.2×	98 1.0×	110 1.2×	36 0.8×	20	403
Young Jin Kim South Korea	12	172 0.7×	268 1.1×	201 2.0×	61 0.7×	46 1.0×	24	437
Silvia Damian Italy	10	124 0.5×	272 1.1×	149 1.5×	143 1.5×	56 1.2×	36	443
Da-zhi Xu China	9	293 1.2×	175 0.7×	163 1.6×	154 1.7×	76 1.7×	12	528
Fan‐ying Liu China	12	249 1.0×	135 0.6×	220 2.2×	89 1.0×	33 0.7×	23	399
Bettina Jesch Austria	10	113 0.4×	291 1.2×	138 1.4×	189 2.0×	95 2.1×	11	433
Leonardo Trani Japan	10	321 1.3×	196 0.8×	51 0.5×	98 1.1×	37 0.8×	21	395

Countries citing papers authored by Xinmin Yu

Since Specialization

Citations

This map shows the geographic impact of Xinmin Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinmin Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinmin Yu more than expected).

Fields of papers citing papers by Xinmin Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinmin Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinmin Yu. The network helps show where Xinmin Yu may publish in the future.

Co-authorship network of co-authors of Xinmin Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xinmin Yu. A scholar is included among the top collaborators of Xinmin Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinmin Yu. Xinmin Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Xinmin, et al.. (2024). Orientation stabilization of light-controlling layers using liquid crystal polymers. Displays. 86. 102893–102893. 1 indexed citations

Yang, Yinxian, Tao Sheng, Xinmin Yu, et al.. (2024). Platelet‐Drug Conjugates Engineered via One‐step Fusion Approach for Metastatic and Postoperative Cancer Treatment. Angewandte Chemie International Edition. 63(37). e202403541–e202403541. 9 indexed citations

Lü, Shun, Xiaorong Dong, Hong Jian, et al.. (2021). Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).. Journal of Clinical Oncology. 39(15_suppl). 9013–9013. 22 indexed citations

Shen, Lin, Ken Kato, Sung‐Bae Kim, et al.. (2021). RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.. Journal of Clinical Oncology. 39(15_suppl). 4012–4012. 34 indexed citations

Socinski, Mark A., Alexander I. Spira, Luis Paz‐Ares, et al.. (2021). AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). TPS9128–TPS9128. 8 indexed citations

Zhou, Caicun, Guanghui Gao, Jun Zhao, et al.. (2019). Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild‐type EGFR and ALK.. Journal of Clinical Oncology. 37(15_suppl). 9112–9112. 22 indexed citations

Jin, Ying, Hua Bao, Xiuning Le, et al.. (2019). Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation.. Journal of Clinical Oncology. 37(15_suppl). e20603–e20603. 1 indexed citations

Song, Zhengbo, Xinmin Yu, & Yiping Zhang. (2017). P3.02c-023 Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma. Journal of Thoracic Oncology. 12(1). S1285–S1286. 1 indexed citations

Jin, Ying, Jianjun Zhang, Ming Chen, et al.. (2017). Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors: A perspective study in NSCLC patients using targeted next generation sequencing.. Journal of Clinical Oncology. 35(15_suppl). e20576–e20576. 1 indexed citations

10.

Sun, Xiaojiang, et al.. (2016). A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer. BMC Cancer. 16(1). 266–266. 21 indexed citations

11.

Song, Zhengbo, Xinmin Yu, & Yiping Zhang. (2015). Chemotherapy and prognosis in advanced thymic carcinoma patients. Clinics. 70(12). 775–780. 11 indexed citations

12.

Xu, Yaping, et al.. (2015). Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.. Journal of Clinical Oncology. 33(15_suppl). e15032–e15032. 2 indexed citations

13.

Shao, Lan, Beibei Zhang, Baochai Lin, et al.. (2014). Efficacy and safety of icotinib in Chinese patients with advanced nonsmall cell lung cancer after failure of chemotherapy. Chinese Medical Journal. 127(2). 266–271. 14 indexed citations

14.

Sun, Yan, Xinmin Yu, & Yiping Zhang. (2014). Renal metastasis after esophagectomy of esophageal squamous cell carcinoma: a case report and literature review. World Journal of Surgical Oncology. 12(1). 165–165. 15 indexed citations

15.

Zhao, Peng, Yiping Zhang, Ying‐Hui Zhu, et al.. (2013). Adenovirus‐mediated Interferon‐γ Gene Therapy Induced Human Pancreatic Carcinoma Capan‐2 Cell Apoptosis In Vitro and In Vivo. The Anatomical Record. 296(4). 604–610. 8 indexed citations

16.

Hong, Wei, Kai Wang, Yiping Zhang, et al.. (2013). Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. Journal of Zhejiang University SCIENCE B. 14(3). 207–215. 18 indexed citations

17.

Xu, Yaping, Xinmin Yu, Qixun Chen, & Weimin Mao. (2012). Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?. World Journal of Surgical Oncology. 10(1). 173–173. 59 indexed citations

18.

Xu, Yaping, Qixun Chen, Xinmin Yu, et al.. (2012). Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: A single institution analysis consisting of 1002 cases. Oncology Letters. 5(1). 185–190. 18 indexed citations

19.

Ma, Shenglin, Yaping Xu, Qinghua Deng, & Xinmin Yu. (2008). Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer. 65(2). 198–203. 110 indexed citations

20.

Xu, Yaping, et al.. (2007). P3-206: Concomitant treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib. Journal of Thoracic Oncology. 2(8). S768–S768. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact